Vedolizumab in Pediatric Patients
Condition: Ulcerative colitis, Crohn's disease
Full Study Name
Takeda - Vedolizumab Phase II in Pediatric Patients With Ulcerative Colitis or Crohn's Disease (IRB no. 48074)
This study focuses on children diagnosed with either Crohn’s disease (CD) or ulcerative colitis (UC) and who are between the ages of 2 and 17. The purpose of the study is to examine how a drug called vedolizumab is processed by the body in these children. Researchers also aim to evaluate whether vedolizumab is safe and effective for the treatment of UC and CD in children and to determine which dose may be best. Vedolizumab belongs to a group of proteins called antibodies, which help to reduce inflammation that can cause the symptoms in CD and UC. The use of vedolizumab in this study is investigational.